About Vivos Therapeutics Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://vivos.com/
Frequently Asked Questions
What is the 52-week range for VVOS?
The 52-week high is $3.42 and the 52-week low is $0.1289.
What is the P/E ratio for VVOS?
The P/E ratio data is currently unavailable.
What is the dividend yield for VVOS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -351.28%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -121.80%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.18.
Analyst Recommendation Trends
Wall Street analyst consensus for VVOS over the last few months:
Latest VVOS News
Most active stocks in Tuesday's session
Curious about the most active stocks on Tuesday? Find out which stocks are dominating the market action!
Vivos Therapeutics Targets $3.6 Million in Annual Cost Reductions as Revenue Growth Initiatives Accelerate
Vivos Therapeutics is implementing a restructuring plan targeting $3. 6 million in annual savings while expanding several revenue initiatives that management believes could support cash flow positivity by late 2026 or early 2027.
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line RevenueLITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other breathing and sleep disorders, today announced execut
Vivos Therapeutics Announces Restructuring And Cost Reduction Plan With An Annual Savings Target Of $3.6M From Q4 2026
Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negotiated contract
These stocks are moving in today's after hours session
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million. InnovAge Holding (NASDAQ:INNV)
Vivos Therapeutics Announces Material Debt Reduction
Company Continues to Make Significant Progress to Enhance Stockholders' Equity and Satisfy Nasdaq Listing RequirementsLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced t
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-14 | SOKOLOW LEONARD J | +12,000 | - | - |
| 2026-09-14 | JOHNSON GREGG C | +12,000 | - | - |
| 2026-07-31 | Amman Bradford K. | +150,000 | $0.41 | $61,500 |
| 2026-07-31 | Amman Bradford K. | +250,000 | $0.41 | $102,500 |
| 2026-06-30 | Huntsman Ronald Kirk | +85,910 | $0.582 | $50,000 |
| 2026-06-30 | Huntsman Ronald Kirk | +85,910 | $0.582 | $50,000 |
| 2026-06-30 | Skaff Michael C | +2,749,330 | $0.582 | $1,600,110 |
| 2026-06-30 | Skaff Michael C | +1,890,164 | $0.582 | $1,100,075 |
| 2026-06-30 | Skaff Michael C | +859,166 | $0.582 | $500,035 |
| 2026-03-31 | Skaff Michael C | +1,783,582 | $1.34 | $2,390,000 |
| 2026-03-31 | Skaff Michael C | +1,783,582 | $1.34 | $2,390,000 |
| 2026-03-31 | Skaff Michael C | +429,957 | $1.34 | $576,142 |
| 2026-03-31 | Skaff Michael C | +308,848 | $1.34 | $413,856 |
| 2026-03-31 | Skaff Michael C | +1,044,777 | $1.34 | $1,400,001 |